Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 8 to April 30, 2024. According to the disclosure reports, the Company repurchased millions of shares during the above period, with detailed records of the number of shares repurchased and the date on which they occurred. The repurchase price presents a different degree of discount or premium compared to the market price. The share repurchase of the series ended on April 30, 2024, on which day the company repurchased 457,300 shares of A-shares for a total payment of RMB20,046,402. According to the regulations, the company has completed the filing of the relevant legal documents and confirmed that all transactions are carried out in accordance with the requirements. Share repurchases may be aimed at enhancing shareholder value or the company's confidence in its share price.

Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 8 to April 30, 2024. According to the disclosure reports, the Company repurchased millions of shares during the above period, with detailed records of the number of shares repurchased and the date on which they occurred. The repurchase price presents a different degree of discount or premium compared to the market price. The share repurchase of the series ended on April 30, 2024, on which day the company repurchased 457,300 shares of A-shares for a total payment of RMB20,046,402. According to the regulations, the company has completed the filing of the relevant legal documents and confirmed that all transactions are carried out in accordance with the requirements. Share repurchases may be aimed at enhancing shareholder value or the company's confidence in its share price.